Table 5.
Overview of gold NPs: structure, pH sensitization method, tumor type, and delivered drug.
| First Author | Publication Year | Structure of NPs | pH Sensitization Method | Tumor Type | Drug |
|---|---|---|---|---|---|
| Aguilar [20] | 2021 | polycaffeic acid-FA-Au | pH-labile catechol-boronic acid linkers | SCC7 squamos cell carcinoma | Bortezomib |
| Essawy [38] | 2020 | Au-hydrazine | pH-labile hydrazone linkers | HBPC oral carcinoma | Doxorubicin |
| Guo [50] | 2018 | Au-Chitosan-AS1411 aptamer | pH-triggered structural changes | A549 lung cancer cell line | Methorexate |
| Kumar [63] | 2020 | Au | pH-labile peptide linker (Lys-Phe-Gly) | BT 474 breast carcinoma | Doxorubicin |
| Liu [81] | 2018 | Au-iron oxide-PEG | pH-labile oleic acid linkers | SGC-7901 gastric adenocarcinoma | Herceptin |
| Mahalunkar [91] | 2019 | Au-PVP-FA | pH-triggered structural changes | MCF-7 breast carcinoma cell line | Curcumin |
| Sun [110] | 2019 | Au-AS1411 aptamer | pH-triggered structural changes | HeLa cervival cancer | Doxorubicin |
Legend: FA, folic acid; Au, gold; PEG, polyethylene glycol; PVP, polyvinylpyrrolidone.